MYRIAD GENETICS INC MYGN

Latest FY: 2025 Healthcare Diagnostics & Research
Market Price $3.03
Market Cap $298.46M
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↓-1.6% YoY
$824.50M
3-Yr CAGR: 6.7%
Net Income ↓-187.4% YoY
-$365.90M
Net Margin: -44.4%
Free Cash Flow ↑33.3% YoY
-$25.60M
FCF Yield: -8.58%
EPS (Diluted) ↓-180.1% YoY
$-3.95
Basic: $-3.95
Return on Equity Efficiency
-99.4%
ROA: -1,457.8%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (MYGN)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2020: Revenue YoY (-25.0%) is identical to Gross Profit YoY (-25.0%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
  • FY 2021: Revenue YoY (+8.1%) is identical to Gross Profit YoY (+8.1%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
  • FY 2022: Revenue YoY (-1.8%) is identical to Gross Profit YoY (-1.8%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
  • FY 2023: Revenue YoY (+11.0%) is identical to Gross Profit YoY (+11.0%). Verify the underlying Revenue and Gross Profit values for FY 2023 and FY 2022.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $753.8M $621.0M $125.3M $1.71 $166.3M $161.3M
FY 2017 $771.4M +2.3% $626.2M $21.8M -82.6% $0.32 -81.3% $106.2M $100.1M -37.9%
FY 2018 $772.6M +0.2% $118.7M $131.1M +501.4% $1.82 +468.8% $115.9M $107.5M +7.4%
FY 2019 $851.1M +10.2% $645.5M $4.6M -96.5% $0.06 -96.7% $83.7M $75.1M -30.1%
FY 2020 $638.6M -25.0% $484.4M $-199.5M -4,437.0% $-2.69 -4,583.3% $60.7M $52.8M -29.7%
FY 2021 $690.6M +8.1% $523.8M $-27.2M +86.4% $-0.35 +87.0% $18.2M $0.2M -99.6%
FY 2022 $678.4M -1.8% $514.5M $-112.0M -311.8% $-1.39 -297.1% $-106.3M $-151.6M -75,900.0%
FY 2023 $753.2M +11.0% $571.3M $-263.3M -135.1% $-3.18 -128.8% $-110.9M $-184.2M -21.5%
FY 2024 $837.6M +11.2% $585.4M $-127.3M +51.7% $-1.41 +55.7% $-8.7M $-38.4M +79.2%
FY 2025 $824.5M -1.6% $576.6M $-365.9M -187.4% $-3.95 -180.1% $1.8M $-25.6M +33.3%
$

Valuation

Market Price $3.03
Market Cap $298.46M
Enterprise Value $268.76M
P/E Ratio N/A
P/B Ratio 0.78
FCF Yield -8.58%
Dividend Yield N/A
Shares Outstanding 94,448,200
%

Profitability & Margins

Gross Margin 69.93%
Operating Margin -46.96%
Net Margin -44.38%
Return on Equity (ROE) -99.43%
Return on Assets (ROA) -1,457.77%
Asset Turnover 32.85x
Revenue 3-Yr CAGR 6.72%
🛡️

Financial Health & Liquidity

Current Ratio 0.26
Cash Ratio 1.54
Debt / Equity 0.326
Debt / Assets 4.777
Cash & Equivalents $149.60M
Total Debt $119.90M
Book Value / Share $3.90
💧

Cash Flow Efficiency

Operating Cash Flow $1.80M
Capital Expenditures (CapEx) $27.40M
Free Cash Flow -$25.60M
OCF / Revenue 0.22%
FCF / Revenue -3.10%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-3.95
EPS (Basic) $-3.95
Dividends / Share N/A
Book Value / Share $3.90
EPS YoY Growth -180.14%
🏛️

Balance Sheet (FY 2025)

Total Assets $25.10M
Total Liabilities $96.90M
Stockholders' Equity $368.00M
Current Assets $25.10M
Current Liabilities $96.90M